Literature DB >> 29629945

Clonal Evolution in Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System.

Julia Garcia-Reyero1,2, Nerea Martinez Magunacelaya2, Ainara Gonzalez Pereña2, Sara Marcos Gonzalez1, Nuria Teran-Villagra1, Ainara Azueta1, Ana Batlle3, Sonia Gonzalez de Villambrosia3, Jose Revert Arce4, Santiago Montes-Moreno1,2,4.   

Abstract

Primary diffuse large B-cell lymphoma (DLBCL) of the central nervous system (CNS) is an aggressive subtype of DLBCL with characteristic clinicopathologic features. Relapse outside the CNS involving extranodal locations has been found in a fraction of cases (16%). Here we describe a case of DLBCL arising in the CNS that relapsed 18 months after the initial diagnosis in the testis and bilateral adrenal glands. Both tumors showed equivalent morphology, phenotype, cytogenetic features, and clonal relationship. Somatic mutation analysis by next generation sequencing demonstrated MYD88L265P mutation in both tumors and de novo CD79B Y196S mutation exclusive to the relapse. The pattern of mutations suggest that the 2 tumors might have evolved from a common progenitor clone with MYD88L265P being the founder mutation. A meta-analysis of the literature shows a significantly high frequency of concurrent MYD88L265P and CD79B ITAM mutations in primary CNS lymphoma and testicular DLBCL, underscoring the role of B cell receptor and nuclear factor kB activation by somatic mutations in these lymphomas that colonize immune-privileged sites. In summary, here we illustrate that targeted next generation sequencing for the detection of hot spot somatic mutations in relapsed DLBCL is useful to confirm ABC phenotype and discovers relevant information that might influence therapeutic decision.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 29629945     DOI: 10.1097/PAI.0000000000000655

Source DB:  PubMed          Journal:  Appl Immunohistochem Mol Morphol        ISSN: 1533-4058


  1 in total

1.  Analysis and evaluation of DRCOP scheme based on polyethylene glycol liposome doxorubicin in patients with diffuse large B-cell lymphoma.

Authors:  Chunyan Liu; Minjuan Zhang
Journal:  Am J Transl Res       Date:  2021-05-15       Impact factor: 4.060

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.